Business
Novo Nordisk Pays $300M Upfront for a Once-Weekly Obesity Pill From China’s Hengrui
The deal, worth up to $2.6 billion, gives Novo an early-stage oral GLP-1/GIP drug designed to be taken once a week — a bid to leapfrog today’s daily pills as its rivalry with Lilly intensifies.